Market Report, "Treatment: Non-Small Cell Lung Cancer In China", Published

Recently published research from Datamonitor, "Treatment: Non-Small Cell Lung Cancer in China", is now available at Fast Market Research

by Bill Thompson

(WireNews+Co) - Boston, MA - 24 January 2013

The treatment of non-small cell lung cancer (NSCLC) in China provides a great commercial opportunity for pharmaceutical companies. Datamonitor surveyed 60 pulmonary oncologists treating NSCLC in mainland China (excluding Hong Kong and Macau) to gain insight into NSCLC diagnosis, patient segmentation, treatment patterns, and prescribing influences.

Scope

- Disease overview assessing etiology, risk factors, symptoms, and patient segmentation.
- In-depth analysis of most common treatment types according to stage at diagnosis and patient characteristics.

Report Highlights

NSCLC treatment algorithms differ in Tier 1 and Tier 2 cities in China, meaning that pharmaceutical companies will need to adjust their marketing strategies accordingly if they are to succeed in market access and distribution in the country.

View Full Report Details (http://www.fastmr.com/prod/529653_treatment_nonsmall_cell_lung_cancer_in_china.aspx) (http://www.fastmr.com/prod/529653_treatment_nonsmall_cell_lung_cancer_in_china.aspx)

Reasons to Get this Report

- Gain insight into the treatment strategies and prescribing trends of 60 physicians treating NSCLC across China.
- Assess NSCLC market potential by identifying where treatment options are not fulfilling patient needs and how physicians select drugs in China.

Report Table of Contents:

Overview
Executive Summary
Methodologies
Research methodologies
Disease Definition and Diagnosis
Disease definition
Etiology
Symptoms
Prognosis
Presentation and diagnosis
Patient Segmentation
Stage distribution
Current Treatment Options
Overview of the available drug classes
Treatment options for earlier stages of NSCLC
Prescribing Trends: Stage IIIA
Adjuvant and neoadjuvant treatment
Prescribing Trends: Stage IIIB
Adjuvant versus neoadjuvant treatment
Prescribing Trends: Stage IV
First-line
Maintenance therapy
Second- and third-line therapy
Beyond third-line therapy the small patient population means there is limited commercial opportunity
Prescribing Trends: Local and Distant Relapse
Local and distant relapse rates
Treatment and prescribing trends: local relapse
Treatment and prescribing trends: distant relapse
Future Therapy
Development of targeted therapies
Future drugs that will likely be used by Chinese physicians
Cytotoxic therapy will remain dominant in the first-line
Table of Contents
Bibliography
Journal papers
Websites
Appendix
Physician data
Contributing experts
Conferences attended

Fast Market Research (http://www.fastmr.com) is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.